As personalized, genomic medicine takes off, four developing countries show the way ... (team and Dr. Federico Goodsaid Associate...)

As personalized, genomic medicine takes off, four developing countries show the way for others

Date:9/19/2008

team and Dr. Federico Goodsaid, Associate Director for Operations in Genomics of the U.S. Food and Drug Administration, as well as Dr. Gerardo Jimenez-Sanchez, Director General of the National Institute of Genomic Medicine.

It looks at challenges and opportuntites for developing coountries and emerging economies as the era of genomic medicine and health approaches. It also identified potential next steps for those already on the journey, and potential entry points for those contemplating getting on board.

There are numerous challenges locally and globally, the latter requiring international collaborative efforts, both North-South and South-South, according to the authors.

The lack of regulatory regimes remains one of the main global challenges to the adoption of genomic medicine. Some regulatory agencies in the West are already preparing for the eventual implementation of genomic medicine in their respective countries.

Says co-author Billie-Jo Hardy: "The inclusion of developing countries, specifically those with emerging economies and existing investments, in the development and harmonization of these regulatory regimes, in concert with attempts to improve scientific capacity through collaborative opportunities, will provide a concrete opportunity to improve the application of genomic medicine to global health."

Next steps

Emerging economies and developing countries with investments in genomic initiatives will need to consider their next steps carefully.

Says Dr. Sguin: "These next steps will need to explore unique niches which can provide them with a competitive advantage, be cost-effective, and should reflect their existing science and technology innovation infrastructure, health needs and health delivery systems."

Among the paper's proposals: 'convergence centres' for science, business and capital -- an evolution beyond science parks and incubators -- aimed at enhancing oppo
'/>"/>

Contact: Terry Collins
terrycollins@rogers.com
416-538-8712
Program on Life Sciences, Ethics and Policy,McLaughlin-Rotman Centre for Global Health
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options
2. Brewing better beer: Scientists determine the genomic origins of lager yeasts
3. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
4. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
5. Rosetta Genomics Reports Second Quarter 2008 Financial Results
6. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
7. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
8. Transgenomic Reports Second Quarter 2008 Results
9. Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress
10. Reminder: Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
11. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast

Post Your Comments:

As personalized, genomic medicine takes off, four developing countries show the way ...(team and Dr. Federico Goodsaid Associate...)